Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Depression - Major Depressive Disorder
Phase PHASE1, PHASE2
Enrollment 67
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Spinal interoceptive pathways (SIPs) convey bodily signals to an interoceptive system in the brain and their dysregulation is linked to major depressive disorder (MDD). Current treatments are partially effective and the role of SIPs in MDD is vastly unexplored. Preliminary data suggests that SIPs are feasible therapeutic targets in MDD. The central hypothesis is that non-invasive spinal cord stimulation will modulate SIPs to elucidate their role and therapeutic potential in MDD using an R61/33 phased innovation approach. R61 phase specific aims (SA). The specific goal will be to evaluate spinal and brain-based SIPs target engagement markers of transcutaneous spinal direct current stimulation (tsDCS) in MDD with two SAs: SA1) To determine tsDCS SIPs modulation using laser-evoked potentials (LEPs) as electroencephalography (EEG)- based neural measures of target engagement. SA2) To evaluate optimal tsDCS dose based upon tolerability and SIPs target engagement markers. Anodal tsDCS will be evaluated as a tool to modulate SIPs in MDD. SIPs (Aδ and C fibers) can be evaluated via LEPs as neural measures (EEG) elicited in MDD-relevant brain regions within an interoceptive system. Prior data shows anodal tsDCS inhibits SIPs and LEPs N2 component will be assessed as tsDCS engagement markers. Adults with MDD (n=67) will participate in a double-blind, crossover, sham-controlled study to evaluate tsDCS at 0,2.5,3, and 3.5 mA. The working hypothesis is that tsDCS will induce a change in LEPs (SA1) in a dose-dependent and tolerable manner (SA2), supporting their use as SIPs engagement markers. Go/No-Go milestones: Compared to sham, the active tsDCS dose that induces a change in LEPs at a preestablished threshold will be evidence of SIPs engagement and "Go" criteria for the R33 phase.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: transcutaneous spinal direct current stimulation — transcutaneous spinal direct current stimulation

Primary Outcomes

  • N2 peak amplitude (5 weeks)
  • N2 latency (5 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-02-25
Completion: 2027-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 67 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Cincinnati
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Francisco Romo-Nava, MD, PhD (PRINCIPAL_INVESTIGATOR) - Lindner Center of Hope/ University of Cincinnati
Contact Information
Study Contact:
Georgi Georgiev
513-536-0731
georgi.georgiev@lindnercenter.org
Georgi Georgiev
513-536-0731
georgi.georgiev@lindnercenter.org
Lindner Center of Hope
Francisco Romo-Nava, MD, PhD
Lindner Center of Hope
Interventions
  • Device: transcutaneous spinal direct current stimulation — transcutaneous spinal direct current stimulation
Study Locations (1 sites)
Lindner Center of Hope, Mason, Ohio 45040 United States
Eligibility Criteria
Inclusion Criteria: * 18 to 60 yrs., inclusive, * Female or Male, * With current MDD episode according to MINI 7.0.2. duration (≥4 weeks and ≤ 2 yrs.), * Current BMI ≥18.5 and ≤ 35.99 kg/mts2 * MADRS score at screening ≥18 * Currently on an FDA- approved antidepressant medication at a stable therapeutic dose for ≥ 8 weeks, * Psychotherapeutic interventions are allowed if dose/frequency stable for ≥4 weeks, * Anxiety disorders allowed if no more than moderate in severity and are not the main diagnosis, * Using an effective contraceptive method (participants with childbearing potential), and 10)Able to complete study related tasks. Exclusion Criteria: * Treatment resistance during current depressive episode (\>2 treatment trials at adequate doses/duration), including medication and neuromodulation treatments. * Current/lifetime diagnosis of bipolar disorder or schizophrenia spectrum disorders. * Significant risk of suicide according to CSSRS or clinical judgment, or suicidal behavior in the past year. * Psychotic symptoms during the current MDD episode or in the past 6 months. * Current (past month) substance use disorder (nicotine, caffeine allowed). * Current unstable neurological conditions including seizure disorders (infantile seizures are not exclusionary), neurodegenerative disorders, or stroke. * Evidence of severe peripheral neuropathy. * History of moderate to severe traumatic brain injury (e.g., skull fracture or loss of consciousness \>10 minutes) or spinal cord injury. * Unstable clinically significant medical conditions (e.g., uncontrolled hypertension as indicated by a systolic \>150 mmHg or diastolic \>95mmHg). * History of cancer allowed if remitted for the past 5 years. * Use of anticonvulsant medications and calcium channel blockers at screening. * Current severe pain conditions or need for chronic use of pain medication including NSAIDs and opiates. * Implanted electronic medical devices. * Neuromodulation interventions in the past month. * Active skin lesions on electrode placement sites. * pregnant or breastfeeding. * Suspected IQ \<80. * Any other relevant clinical reason as judged by the clinician.
Conditions Breast Cancer
Phase NA
Enrollment 116
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research is to evaluate the effectiveness of a multidisciplinary pain management program for AIMSS in reducing pain, subjective cognitive complaints, psychological distress, and impaired functional status resulting in improved adherence to Aromatase Inhibitor medications compared to usual care. We want to identify predictors of improvement in pain, functional status, subjective cognition and mood following participation in the program.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Cognitive Behavioral Therapy based Pain Management Program — Subjects will participate in a two-day structured class that will focus on Cognitive-Behavioral skills and strategies to improve pain control, fatigue, sleep disturbance, cognitive symptoms, and stress while educating patients on the efficacy of Aromatase Inhibitors in prolonging cancer-free survival with the goal of eliminating non-adherence.

Primary Outcomes

  • Adherence to Aromatase Inhibitors (AIs) (Baseline, 3 months, 6 months)
  • AIMSS Follow-up Questionnaire (Baseline, 3 months, 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-06
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 116 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Barbara Bruce, Ph.D., LP (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Alejandra Cuartas-Abril, M.S.
904-956-8885
Cuartas-Abril.Alejandra@mayo.edu
Alejandra Cuartas-Abril, M.S.
904-956-8885
Mayo Clinic in Florida
Barbara K Bruce
Mayo Clinic in Florida
Interventions
  • Behavioral: Cognitive Behavioral Therapy based Pain Management Program — Subjects will participate in a two-day structured class that will focus on Cognitive-Behavioral skills and strategies to improve pain control, fatigue, sleep disturbance, cognitive symptoms, and stress while educating patients on the efficacy of Aromatase Inhibitors in prolonging cancer-free survival with the goal of eliminating non-adherence.
Study Locations (1 sites)
Mayo Clinic in Florida, Jacksonville, Florida 32224 United States
Eligibility Criteria
Inclusion Criteria: * At least 18 years old * ECOG ≤ 2 * Stage 0-III HR+ breast cancer in need of strategies to reduce symptoms and improve quality of life Exclusion Criteria: • Less than 18 years of age. \- Stage 4 HR+ breast cancer
Conditions Postpartum Depression (PPD), Pregnancy
Phase Not Applicable
Enrollment 500
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to develop a blood test that may be predictive of postpartum depression. This Blood test is investigational and not yet FDA approved. Participants will not receive the results of this blood test. Up to 500 pregnant women will be recruited for the study from 2 sites. Participants must be age 18 or above with a singleton pregnancy and able to provide written consent in English. The Objective of this Clinical Trial is to prospectively validate the Enlighten Device test by prospectively determining false/true positive and negative rates. Building off of this, an exploratory objective of this study is to examine clinical factors associated with false positive/negative rates. This project will address the following Aim: Aim 1: Prospective collection of true/false positive and negative PPD outcomes through 6 months postpartum. Primary Hypothesis H1a: 80% or greater of pregnant women who develop PPD by 3 months after delivery will be determined to be Biomarker Positive by the Enlighten Device in T3. Primary Hypothesis H1b: 10% or fewer of pregnant women who are determined to be Biomarker Negative by the Enlighten Device in T3 will develop PPD by 3 months after delivery. Exploratory Aim 1: Investigation of clinical factors that may be associated with false positive and false negative rates, such as: medication use, stressful life events, and sociocultural context. Participants will be screened during the second or third trimester and enrolled during the third trimester, before week 30 weeks of gestation. Participants may self- identify through study advertisements in participating clinics, social media outlets, and community outreach efforts. Enrolled participants will undergo blood collection during their 3rd trimester (\~27-30 weeks, a standard pregnancy-related blood collection timepoint) for completion of the Enlighten Device test, the blood-based epigenetic biomarker test. Participants will then be interviewed at 2 weeks, 6 weeks, 3 months, and 6 months postpartum for the development of depression symptoms. They'll also complete a multitude of other outcome measures at each of these visits.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Enlighten — The primary analysis will examine the performance of the Enlighten Device by evaluating biomarker status results ("elevated risk" or "low risk") at the third trimester against depression symptoms outcome data collected by the 3 months postpartum time point.

Primary Outcomes

  • Percentage of Participants with True/False Positive and Negative PPD Outcomes as Assessed by the Enlighten Device (6 months postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-20
Completion: 2028-07-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Virginia
Principal Investigators:
  • Jennifer L Payne, MD (PRINCIPAL_INVESTIGATOR) - University of Virginia
  • Andrea Cubitt, PhD (PRINCIPAL_INVESTIGATOR) - Dionysus Digital Health, Inc.
Contact Information
Study Contact:
Meeta Pangtey, MPH
434-987-7367
uwp7jh@uvahealth.org
Lauren A Williamson, PhD
434-987-7369
lea6d@uvahealth.org
Scott A Sullivan, MD
843-817-9046
Scott.Sullivan@inova.org
Inova Health System
Interventions
  • Diagnostic Test: Enlighten — The primary analysis will examine the performance of the Enlighten Device by evaluating biomarker status results ("elevated risk" or "low risk") at the third trimester against depression symptoms outcome data collected by the 3 months postpartum time point.
Study Locations (2 sites)
University of Virginia, Charlottesville, Virginia 22903 United States
Inova Health System, Falls Church, Virginia 22042 United States
Eligibility Criteria
Inclusion Criteria: * subject must be pregnant (singleton pregnancy) * \<30 weeks' gestation, age 18 or above * able to provide written consent in English Exclusion Criteria: * The study team and/or PI may exclude anyone deemed unsafe to participate in the protocol.
Conditions Depression, Bipolar Affective Disorder, ...
Phase NA
Enrollment 325
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The project proposes to develop a digital product based on cognitive behavioral therapy for the assisted treatment of depression. The digital cognitive behavioral therapy in this study is conducted based on a self-developed mobile applet. The therapy is developed by psychotherapists, which is conducted for a total of 8 weeks, with weekly sessions including AI-guided course work and homework. This study aims to evaluate the therapeutic effects of CBT-based digital products for depression in patients through a real-world study, and to explore its genetic and neuroimaging mechanisms.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: a digital product based on CBT — The digital cognitive behavioral therapy in this study is conducted based on a self-developed mobile applet. The therapy is developed by psychotherapists, which is conducted for a total of 8 weeks, with weekly sessions including Al-guided course work and homework.

Primary Outcomes

  • Change from baseline in Hamilton Depression Rating Scale (HAMD) (Week 4 and 8 of treatment duration)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-13
Completion: 2026-12-31
Eligibility
Age: 14 Years and older
Sex: ALL
Volunteers: false
Enrollment: 325 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University
Contact Information
Study Contact:
Weihua Yue
86-010-82805307
dryue@bjmu.edu.cn
Weihua Yue
86-010-82805307
dryue@bjmu.edu.cn
Peking University Sixth Hostipal
Interventions
  • Device: a digital product based on CBT — The digital cognitive behavioral therapy in this study is conducted based on a self-developed mobile applet. The therapy is developed by psychotherapists, which is conducted for a total of 8 weeks, with weekly sessions including Al-guided course work and homework.
Study Locations (1 sites)
Peking University Sixth Hostipal, Beijing, Beijing Municipality 100191 China
Eligibility Criteria
Inclusion Criteria: 1. Aged 14-60 years (including 14 and 60), no gender restriction; 2. HAMD \>= 14; 3. Written informed consent obtained from the patient; written informed consent obtained from the guardian for minors. Exclusion Criteria: * Persons with severe suicidal tendencies (item 10 of the MADRS scale ≥ 5).
Conditions Atrial Fibrillation (AF), Hypertension, ...
Phase NA
Enrollment 1250
Locations 50 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study will verify if a structured multidisciplinary approach (called iABC), aimed to improve the appropriate management of elderly AF patients with multimorbidity (the i-ABC group), would provide a clear evidence of an improvement in clinical conditions and quality of life compared to usual clinical care. The i-ABC group in AFFIRMO will follow the ABC pathway, focused on three domains: avoid stroke with anticoagulation (with optimized VKA or label-adherent DOAC use); better symptom management; and optimized management of associated cardiovascular and non cardiovascular comorbidities. The study will be conducted in Bulgaria, Denmark, Italy, Romania, Serbia and Spain .

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Other: iABC platform use — The novel platform (iABC) that will be used in AFFIRMO will consist of an educational program, a healthy or functional diet/physical activity, guideline-adherent drug treatments, periodic (re)assessment.

Primary Outcomes

  • Impact of iABC on all cause unplanned hospitalization (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-11
Completion: 2026-01-31
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Heart Care Foundation
Collaborators: Aalborg University, University of Belgrade, Universidad de Murcia, Carol Davila University of Medicine and Pharmacy, Plovdiv Medical University, University of Liverpool
Contact Information
Study Contact:
Aldo P Maggioni, MD
+390555101211
affirmo@heartcarefoundation.it
ANTONY GOGOV, MD
MHAT Haskovo AD-Cardiology
KOSTADIN KICHUKOV, MD
SHATS Sveti Georgi - Pernik-Cardiology
Interventions
  • Other: iABC platform use — The novel platform (iABC) that will be used in AFFIRMO will consist of an educational program, a healthy or functional diet/physical activity, guideline-adherent drug treatments, periodic (re)assessment.
Study Locations (50 sites)
MHAT Haskovo AD-Cardiology, Haskovo, Bulgaria
SHATS Sveti Georgi - Pernik-Cardiology, Pernik, Bulgaria
MBAL Sv. Ivan Rilski-Cardiology, Plovdiv, Bulgaria
UMBAL Sveti Georgi EAD-Clinic of Cardiology, Plovdiv, Bulgaria
UMHAT Pulmed Plovdiv-Cardiology, Plovdiv, Bulgaria
Acibadem City Clinic Tokuda Hospital-Dept of Electrophysiology Clinic of Cardiology, Sofia, Bulgaria
Acibadem City Clinic UMBAL Cardiovascular Center-CARDIOLOGY, Sofia, Bulgaria
National Heart Hospital-ICCU, Sofia, Bulgaria
Herlev Hospital-Department of Cardiology, Herlev, Denmark
North Denmark Regional Hospital-Department of Cardiology, Hjørring, Denmark
Eligibility Criteria
Inclusion Criteria: * Outpatients of both sexes with age ≥65 years; * First diagnosed, paroxysmal, persistent, long-standing persistent or permanent AF, confirmed as per guideline-recommended diagnostic criteria for AF, e.g. with electrocardiogram (ECG) or Holter monitoring; * ≥1 additional long-term comorbidity, thus fulfilling the definition of multimorbidity: hypertension (treated with at least 2 antihypertensive drugs), coronary artery disease (CAD), peripheral artery disease, heart failure, stroke/TIA, diabetes mellitus, COPD, CKD. Exclusion Criteria: * Mechanical prosthetic heart valve or moderate/severe mitral stenosis; * Patient unwilling to be enrolled and sign written informed consent; * Patient unable to understand the study and attend the follow-up; * Serious diseases with a life expectancy inferior to 12 months; * Patients included in other interventional studies. Only for sites randomized to the iABC group: \- Patient without a device suitable for iABC use.
Conditions Depression Anxiety Disorder
Phase PHASE2, PHASE3
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to assess the effect of commercial multi-strains psychobiotics supplementation as an ad-on therapy on depressive symptoms and metabolic syndrome components (HDL-C, FPG, TGs, WC, BP) in adult depressed patients with pre-metabolic syndrome and metabolic syndrome. The second goal is to explore the effect of commercial multi-strains psychobiotics supplementation on the anthropometric measurement (weight, body mass index (BMI)) in adult depressed patients with pre-metabolic syndrome and metabolic syndrome. The main questions they aim to answer are: * Will commercial multi-strains psychobiotics supplementation help to ease depressive symptoms as an ad-on therapy in patients with pre-metabolic syndrome and metabolic syndrome? * Will commercial multi-strains psychobiotics supplementation improve anthropometric measurements and metabolic syndrome components (WC, FPG, BP, TGs, HDL-C) in depressed patients? Researchers will compare psychobiotics to a placebo (a look-alike substance that contains no drug) to see if psychobiotics work to improve depression and metabolic syndrome components. Participants will: * Be examined for depression, anxiety, and metabolic syndrome components (waist circumference, diabetes, blood pressure, triglycerides, and high-density lipoprotein). * Be asked to conduct laboratory tests to determine the inclusion and exclusion criteria. * Be given probiotics/ placebo to consume every day for 3 months (12 weeks). * Repeat the examination and laboratory tests to determine the results. * Be followed up weekly for adverse events and to insure their compliance with the study instructions. * Be followed up after 4 weeks as an end-visit and will conduct the examination and the laboratory blood tests.

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Winclove's Ecologic® Barrier Probiotics — The investigational product is a multispecies probiotic formulation consisting of 9 selected probiotic strains: the following bacterial strains: Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58.
  • Dietary Supplement: Winclove's Ecologic® Barrier Probiotics Placebo — The placebo is composed of the carrier of the probiotic product that are identical in physical appearance, it includes maize starch and maltodextrins but contains no bacteria.

Primary Outcomes

  • Psychological Assessment (depression1) (at baseline, after the end of the 12th week of the intervention, and after 4 weeks post-intervention follow-up (end visit).)
  • Psychological Assessment (depression2) (at baseline, after the end of the 12th week of the intervention, and after 4 weeks post-intervention follow-up (end visit).)
  • Psychological Assessment (Anxiety) (at baseline, after the end of the 12th week of the intervention, and after 4 weeks post-intervention follow-up (end visit).)
  • Anthropometric Measurements (at baseline, after the end of the 12th week of the intervention, and after 4 weeks post-intervention follow-up (end visit).)
  • Metabolic Syndrome Components (Waist circumference) (at baseline, after the end of the 12th week of the intervention, and after 4 weeks post-intervention follow-up (end visit).)
  • Metabolic Syndrome Components (Medical Assessments/ Laboratory Tests) (at baseline, after the end of the 12th week of the intervention, and after 4 weeks post-intervention follow-up (end visit).)
  • Metabolic Syndrome Components (Medical Assessments/ Blood Pressure) (at baseline, after the end of the 12th week of the intervention, and after 4 weeks post-intervention follow-up (end visit).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2025-03-02
Completion: 2027-01-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Roaa Ahmed Alkreadees
Contact Information
Study Contact:
Roaa A Alkreadees
00966555527073
442203635@student.ksu.edu.sa
Roaa A. Alkreadees, MS
966555527073
442203635@student.ksu.edu.sa
King Saud University Medical City
Interventions
  • Dietary Supplement: Winclove's Ecologic® Barrier Probiotics — The investigational product is a multispecies probiotic formulation consisting of 9 selected probiotic strains: the following bacterial strains: Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58.
  • Dietary Supplement: Winclove's Ecologic® Barrier Probiotics Placebo — The placebo is composed of the carrier of the probiotic product that are identical in physical appearance, it includes maize starch and maltodextrins but contains no bacteria.
Study Locations (1 sites)
King Saud University Medical City, Riyadh, Riyadh Region Saudi Arabia
Eligibility Criteria
Inclusion Criteria: * Major Depression Disorder (MDD) patients on antidepressants for at least 4 weeks or more. * MDD patients with pre-metabolic syndrome (at least 2 of the MetS components) and metabolic syndrome (at least 3 of the following components: central obesity with WC for men ≥ 94 centimeters while for women ≥ 80 centimeter, increased FPG ≥ 100 mg/dl, increased BP to ≥ 130 / ≥ 85 mmHg, increased TGs equal or above 150 mg / dl, increased HDL cholesterol for men to \< 40 mg / dl while for women \< 50 mg / dl) (IDF., 2006). * MDD patients with other comorbid diseases such as anxiety. Exclusion Criteria: * Patients using any other supplements to improve mood. * Patients using pre/pro/symbiotics supplement or antibiotics during the last 3 weeks before the intervention. * Patients with chronic diseases (cardiac, renal, or hepatic diseases) * Patients with gastro intestinal diseases (Crohn's disease, ulcerative colitis). * Patients with infectious diseases (HIV/AIDS). * Cancer patients or those undergoing chemotherapy. * Patients with food allergies such as gluten intolerance or lactose intolerance. * Pregnant and breastfeeding women. * Patients with modified antidepressant dose during interventional period or receiving psychotherapy during the intervention. * Patients with thyroid disorder. * Patients following a diet to lose weight during the intervention. * Diabetic patients who are insulin-dependent. * patients receiving injections or medications to lose weight (Ozempic, Mounjaro …etc) either 3 weeks before or during the intervention. * Patients using plasma-lipid lowering drug for less than 1 month before the intervention. * Patients with substance abuse including alcohol addiction.
Conditions Psoriatic Arthritis, Depression, Psoriat...
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The investigators seek clinically actionable understanding of the mechanisms that underlie depression in the context of immune mediated inflammatory diseases (IMIDs), delivered by a focused immune intervention study examining brain circuitry using state of the art imaging in the context of exquisitely specific therapeutic immune interception in human immune disease. Glutamate concentration in the NAcc will be positively correlated with the magnitude of the inflammatory response and will be attenuated by IL-17A inhibition. Ultimately, this will be associated with an improvement in depressive symptoms. The strength of coupling between early and late systems will be attenuated in the context of IL-17A-driven inflammation and will be correlated with less frequent switching behaviour following negative outcomes and ultimately depressive symptoms. This coupling will be re-established following IL-17 antagonism. Patients whose depressive symptoms benefit most from IL-17A antagonism will exhibit greatest resting-state and task-specific functional connectivity between Th-NAcc.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Secukinumab — Initial dosing of Secukinimab at week 0, 1, 2, 3, 4 and maintenance doses will be determined by the standard care team. This will be 150mg or 300mg. This will be administered by the study team once confirmed and randomisation has occurred for secukinimab/ placebo allocation.
  • Drug: Bimekizumab — Initial dosing of bimkizumab at week 0 \& 4 and maintenance doses will be determined by the standard care team. This will be 160mg or 320mg. This will be administered by the study team once confirmed and randomisation has occurred for bimekizumab/ placebo allocation.
  • Drug: Ixekizumab — Initial dosing of Ixekizumab at week 0 \& 4 or week 0, 2 \& 4, maintenance doses will be determined by the standard care team. The initial dose will be 160mgs then 80mg dose will either be given 2 or 4 weekly. This will be administered by the study team once confirmed and randomisation has occurred for Ixekizumab/ placebo allocation.
  • Drug: Placebo — Sodium chloride 0.9% for injection will be used as a placebo. A 1ml volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection in line with the Secukinumab/ Bimekizumab/ Ixekizumab dosing regimen. No dose adjustments are permitted.

Primary Outcomes

  • Changes in glutamate concentration in the NAcc as measured by 7T MRS. (Week 0 to Week 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-06-02
Completion: 2027-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NHS Greater Glasgow and Clyde
Collaborators: University of Glasgow, Medical Research Council
Principal Investigators:
  • Jonathan Cavanagh, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of Glasgow
Contact Information
Study Contact:
Maxine Arnott, BSc
07890 059695
maxine.arnott@glasgow.ac.uk
Neil Basu, MD, PhD
neil.basu@glasgow.ac.uk
Maxine Arnott
07890059695
maxine.arnott@glasgow.ac.uk
Queen Elizabeth University Hospital
Interventions
  • Drug: Secukinumab — Initial dosing of Secukinimab at week 0, 1, 2, 3, 4 and maintenance doses will be determined by the standard care team. This will be 150mg or 300mg. This will be administered by the study team once confirmed and randomisation has occurred for secukinimab/ placebo allocation.
  • Drug: Bimekizumab — Initial dosing of bimkizumab at week 0 \& 4 and maintenance doses will be determined by the standard care team. This will be 160mg or 320mg. This will be administered by the study team once confirmed and randomisation has occurred for bimekizumab/ placebo allocation.
  • Drug: Ixekizumab — Initial dosing of Ixekizumab at week 0 \& 4 or week 0, 2 \& 4, maintenance doses will be determined by the standard care team. The initial dose will be 160mgs then 80mg dose will either be given 2 or 4 weekly. This will be administered by the study team once confirmed and randomisation has occurred for Ixekizumab/ placebo allocation.
  • Drug: Placebo — Sodium chloride 0.9% for injection will be used as a placebo. A 1ml volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection in line with the Secukinumab/ Bimekizumab/ Ixekizumab dosing regimen. No dose adjustments are permitted.
Study Locations (1 sites)
Queen Elizabeth University Hospital, Glasgow, Scotland G51 4TF United Kingdom
Eligibility Criteria
Inclusion Criteria: * Adults ≥18 years \< 75years * Diagnosis of PsO or PsA, made by a dermatologist or rheumatologist. * Selected to start secukinumab/ bimekizumab/ Ixekizumab as part of their standard clinical care by their usual dermatology team for PsO or rheumatology clinical team for PsA in line with the license for secukinumab/ bimekizumab/ Ixekizumab and NICE/SMC criteria. * No contraindications to MRI (for example metal fragments or implantable devices not compatible with MRI. (no extra x-ray images will be obtained to check placement of metal fragments or clips insitu. Existing images may be used to check for possible contraindications) * Satisfactory completion of standard pre-biologic safety screening (including, but not limited to, exclusion of latent TB infection according to local protocol, chest X-ray, negative HIV screen, negative Hepatitis screen antibody, negative Hepatitis B surface antigen \[Hep B sAg\] and negative Hepatitis B anti-core antibody \[Hep B cAb\]) * Recent (but not within 4 weeks prior baseline) use of intra-muscular or intra-articular steroid injections * Women of Child-Bearing Potential (WoCBP) must be willing to use effective contraception for study duration. Further information is provided in appendix 1. * Willing to participate and give informed consent Exclusion Criteria: * Inability to provide written informed consent * Severe physical impairment (e.g., blindness, deafness, paraplegia). * Clinically important, active infections e.g. active TB * History of inflammatory bowel disease * Pregnant or breast feeding * Severe claustrophobia precluding MRI * Contraindications to 7T MRI (metal implants in the ears, head or neck, microbladed/ tattooed eyebrows, metal fragments in the eyes) * Confounding neurological disease including MS, Stroke, Traumatic Brain Injury * Previous exposure to IL-17A, IL-17A/F, IL-17R inhibitors or IL-23 p19/p40 inhibitors in the last 6 months * Hypersensitivity to any of the excipients in secukinumab/ bimekizumab/ ixekizumab. * Any reason which, at the investigator's discretion, would make them unsuitable to take part in the study.
Conditions Preeclampsia, Preeclampsia Postpartum
Phase EARLY_PHASE1
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. Importantly, women who had preeclampsia have an exaggerated vascular responsiveness to hypertensive stimuli, such as high-salt intake, compared to women who had a healthy pregnancy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. While the association between a history of preeclampsia and vascular dysfunction leading to elevated CVD risk is well known, the mechanisms underlying this dysfunction remains unclear. The purpose of this study is to examine the role of vascular mineralocorticoid receptor, the terminal receptor in the angiotensin system that contributes to blood pressure regulation, in mediating exaggerated microvascular endothelial dysfunction before and after a high-salt stimulus. This will help us better understand the mechanisms of microvascular dysfunction these women, and how inhibition of these receptors may improve microvascular function. In this study, we use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) we examine the blood vessels in a nickel-sized area of the skin.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Drug: Eplerenone — Local heating: eplerenone is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response.

Primary Outcomes

  • Change in microvascular endothelial function following local eplerenone treatment compared to placebo treatment measured by laser-Doppler flowmetry (Day 3 (low-salt diet run in) and Day 10 (low-salt diet + high-salt supplement))
  • Changes in 24-hour urine sodium (Day 2, Day 9)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2025-01-02
Completion: 2027-11-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Anna Stanhewicz, PhD
Principal Investigators:
  • Anna Reid-Stanhewicz, PhD (PRINCIPAL_INVESTIGATOR) - University of Iowa
Contact Information
Study Contact:
Kelsey Schwartz, PhD
319-467-1732
kelsey-schwartz@uiowa.edu
Kelsey Schwartz, PhD
319-467-1732
kelsey-schwartz@uiowa.edu
University of Iowa
Claire Goebel
319-335-1914
claire-goebel@uiowa.edu
University of Iowa
Interventions
  • Drug: Eplerenone — Local heating: eplerenone is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response.
Study Locations (1 sites)
University of Iowa, Iowa City, Iowa 52242 United States
Eligibility Criteria
Inclusion Criteria: * women who had preeclampsia and women who did not have preeclampsia * 12 weeks to 5 years postpartum * 18-45 years old Exclusion Criteria: * history of hypertension or metabolic disease before pregnancy * history of gestational diabetes * history of gestational hypertension without preeclampsia * skin diseases * current tobacco use * current antihypertensive medication * statin or other cholesterol-lowering medication * currently pregnant * body mass index less than 18.5 kg/m2 * allergy to materials used during the experiment.(e.g. latex), * known allergy to study drugs or salt-supplement
Conditions Arterial Hypertension
Phase Not Applicable
Enrollment 10000
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The quality of primary healthcare systems for patients with hypertension (HTA) in Morocco is a critical issue due to its high prevalence and significant impact on morbidity and mortality. The concept of "quality in primary care" encompasses fundamental aspects such as timeliness, accessibility, and the provision of care based on current clinical guidelines and recommendations from professional societies. This observational study on hypertension (HTA) uses an electronic registry accessible remotely to collect medical data from primary care and hospital settings. Investigators will be trained to ensure standardization in blood pressure measurements to minimize errors. The registry will include clinical, therapeutic, and complication data for patients aged 18 and over with a confirmed diagnosis of HTA, with information transmitted anonymously via a certified secure channel. Informed consent from patients will be required for including their data in the registry. Collected data will include anthropometric measurements (weight, height, waist circumference, body mass index), blood pressure measurements by validated devices or ambulatory measurements, and metabolic assessments (blood glucose, total cholesterol, triglycerides, LDL, HDL, urea, creatinine, uric acid, urine albumin-to-creatinine ratio). Cardiovascular complications will also be recorded. The study design is a cohort study with a cross-sectional perspective and a targeted follow-up period of one year. The study aims to evaluate the prevalence and phenotypes of HTA in Morocco, as well as the geographic distribution of the disease. It will compare current data with those from previous years and other North African countries to assess the applicability of Moroccan clinical practices and recommendations from the European Society of Cardiology (ESC). The goal is to enhance the understanding and management of HTA, as well as to optimize prevention and treatment strategies. This comprehensive analysis will help identify potential gaps in primary care and develop strategies to improve the management of hypertensive patients. The comparative evaluation of data related to examinations, treatments, and complications of the cohort of patients followed for hypertension during the period 2024-2026, in comparison with results from previous years and other countries, will provide valuable insights into the shortcomings and progress in care delivery. This approach will not only identify areas needing improvement but also highlight significant advances in hypertension management.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Prevalence of arterial hypertension (At inclusion)
  • To assess the distribution of HTA across the kingdom (At inclusion)
  • To analyze the various phenotypes of primary and secondary hypertension as well as the associated complications (At inclusion)
  • Causal relationships between Arterial Hypertension and various complications (At inclusion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-21
Completion: 2027-01-21
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Moroccan Society of Cardiology
Collaborators: F&C Clinical Trials
Contact Information
Study Contact:
F&C Clinical Trials
+33 7 69 27 88 10
infos@fc-ct.com
Mbarek NAZZI
+2126663888
Mbarek.nazzi@gmail.com
Moroccan Society of Cardiology
Mbarek NAZZI
Moroccan Society of Cardiology
Interventions
N/A
Study Locations (5 sites)
Moroccan Society of Cardiology, Meknes, Morocco Morocco
Moroccan Society of Cardiology, Casablanca, Morocco
UM6SSP, Casablanca, Morocco
Ibn Sina Hospital Center, Rabat, Morocco
Mohamed V Military Hospital, Rabat, Morocco
Eligibility Criteria
Inclusion Criteria: * Individuals aged over 18 years. * Patients with blood pressure: * Higher than 140 mmHg systolic and/or higher or equal to 90 mmHg diastolic in consultation or in a hospital setting. * Higher than 135/85 mmHg at home or in ambulatory blood pressure measurements (ABPM). * Patients who have agreed and signed the informed consent. * Patients with legal status in the Moroccan kingdom. Exclusion Criteria: * Patient without diagnosis of hypertension * Patient under 18 years old * Patients refusing to sign the informed consent. * Patients with illegal status in the kingdom.
Conditions HER2-negative Breast Cancer Patients Wit...
Phase PHASE2
Enrollment 120
Locations 12 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receive treatment of utidelone alone or in combination with capecitabine. The objectives both in stage I and stage II are to evaluate the intracranial and systemic efficacy and safety of utdelone plus capecitabine for the treatment of HER2-negative breast cancer patients with brain metastases.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Utidelone — Utidelone 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle.
  • Drug: Utidelone in combination with capecitabine — UTD1 25 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
  • Drug: Utidelone in combination with capecitabine — Utidelone 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
  • Drug: Utidelone in combination with capecitabine — Utidelone 25 mg/m2/d or 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.

Primary Outcomes

  • Intracranial Objective Response Rate (IC-ORR) evaluated by investigator according to RECIST 1.1 criteria. (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-07-14
Completion: 2027-07-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Biostar Pharma, Inc.
Contact Information
Study Contact:
Simon Guan
+86 10 67864938
simon.guan@biostar-pharma.com
Dr. Hope S. Rugo
hrugo@coh.org
City of Hope--Duarte
Dr. Hannah Chang
hanchang@coh.org
City of Hope--Duarte
Interventions
  • Drug: Utidelone — Utidelone 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle.
  • Drug: Utidelone in combination with capecitabine — UTD1 25 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
  • Drug: Utidelone in combination with capecitabine — Utidelone 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
  • Drug: Utidelone in combination with capecitabine — Utidelone 25 mg/m2/d or 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle plus capecitabine 1000 mg/m2 orally twice a day, for 1 to 14 days, 21 days as a treatment cycle.
Study Locations (12 sites)
City of Hope--Duarte, Duarte, California 91010 United States
Univ. of California Los Angeles, Los Angeles, California 90095 United States
Scripps Health, San Diego, California 92121 United States
University Of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado 80045 United States
Augusta University, Augusta, Georgia 30912 United States
Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago, Illinois 60611 United States
The Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21287 United States
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada 89169 United States
Stony Brook Cancer Center, Stony Brook, New York 11794-7263 United States
MD Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: 1. Have histologically confirmed HER2-negative metastatic breast cancer. HER2-negative defined as immunohistochemical (IHC) score of 0 or 1+, or IHC2+ with negative HER2 expression on in situ hybridization (ISH). 2. Based on screening contrast-enhanced brain MRI, patients must have at least one measurable intracranial lesion according to RECIST 1.1 (≥1.0 cm in size) . 3. Male or female aged ≥18 years. 4. ECOG PS 0 or 1. 5. Have a life expectancy of at least 3 months. 6. Have adequate baseline hematologic parameters. 7. Have adequate hepatic and renal function. 8. ≤ 3 prior lines of chemotherapy in advanced or metastatic setting. 9. Women of childbearing potential, unless hysterectomy or oophorectomy or postmenopausal for at least 12 consecutive months, must use an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives \[any hormonal method in conjunction with a secondary method\], intrauterine device, female condom with spermicide, diaphragm with spermicide, absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile \[at least 6 months prior to study drug administration\] sexual partner) for at least 4 weeks prior to study drug administration, during study and up to 6 months following the last dose of study drug. Cessation of birth control after this point should be discussed with a responsible physician. Investigator will discuss with patient on the above points and the patient agreement will be documented in the source document. The investigator should ensure that the patient is using an effective method of avoiding pregnancy as per protocol. In case of Male patients: Either patient partners or patients themselves must use an effective method of avoiding pregnancy for at least 4 weeks prior to study drug administration, during study and up to 6 months following the last dose. 10. Patients must be able to follow the study visit schedule, and must be able of sign and give informed consent in accordance with institutional review board. Exclusion Criteria: 1. Leptomeningeal metastasis confirmed by MRI and/or cerebrospinal fluid cytology. 2. Any intracranial lesion thought to require immediate local therapy, including (but not limited to) a lesion in an anatomic site where increase in size or possible treatment-related edema may pose risk to patient (e.g. brain stem lesions). 3. Have poorly controlled (\> 1/week) generalized or complex partial seizures, or manifest neurologic progression due to brain metastases notwithstanding CNS-directed therapy. 4. Had evidence of intracranial hemorrhage within 3 months before study treatment. 5. Had evidence of hemoptysis within 6 months before study treatment. Or bleeding or evidence of coagulopathy within 4 weeks before study treatment. 6. Undergone major surgical procedures within 4 weeks or not fully recovered from surgery before study treatment. 7. Patients who have received anti-tumor therapies less than 2 weeks before the first dose of investigational product, including endocrine therapy, chemotherapy, radiotherapy, biotherapy, targeted therapy, immunotherapy or antibody-drug conjugate therapy. 8. Persistent toxicities caused by previous antitumor therapy (excluding alopecia), not yet improved to CTCAE v5.0 grade ≤ 1 or baseline. 9. Patients with neuropathy\> grade 1. 10. Known hypersensitivity to any components of the investigational product. 11. Known deficiency of dihydropyrimidine dehydrogenase (DPD). 12. This applies only to the combination cohort and does not apply to the monotherapy cohort. For patients with previous capecitabine treatment, the prior use of capecitabine meets any of the following criteria: A) The best response during prior capecitabine combination therapy or monotherapy is Progressive Disease (PD); B) Have received capecitabine treatment within 6 months prior to the first study treatment. 13. Patients who are pregnant (positive pregnancy test) or lactating. 14. Patients with other malignancies over the past 5 years, except for inactive tumors with good prognosis, including resected basal cell and squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, or papillary thyroid cancer. 15. Patients who are particpating in other interventional studies or who are receiving other study treatments (patients who have discontinued other investigational treatments and are in follow-up are eligible for enrollement in this study). 16. Known active or uncontrolled hepatitis B infection, active syphilis, or HIV infection that is not well controlled; or positive for hepatitis B virus based on the evaluation of results of tests for hepatitis B (HBsAg, anti-HBs, anti-HBc, or HBV DNA) infection at screening. 17. With a history of severe or uncontrolled diseases. 18. Autoimmune diseases requiring treatment with systemic glucocorticoids. 19. Not able to perform contrast-enhanced brain MRI or known contraindications to MRI gadolinium contrast, such as cardiac pacemaker, shrapnel, or eye foreign body. 20. Patients with a history of other systemic severe diseases or abnormal laboratory findings that would, in the Investigator's judgment, be inappropriate for this study.
Conditions Breast Cancer Metastatic
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To investigate the real-world efficacy and safety of Sacituzumab govitecan for HER2 negative metastatic breast cancer patients in China.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • PFS (from enrollment to progression or death (for any reason),assessed up to 100 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-02-01
Completion: 2026-12-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zhejiang Cancer Hospital
Principal Investigators:
  • Xiaojia Wang, MD; Ph.D (PRINCIPAL_INVESTIGATOR) - Zhejiang Cancer Hospital
  • Qin Wu, Ph.D (PRINCIPAL_INVESTIGATOR) - Hangzhou Institute of Medicine (HIM)
  • Huanhuan Zhou, MD (PRINCIPAL_INVESTIGATOR) - Zhejiang Cancer Hospital
Contact Information
Study Contact:
Xiaojia Wang, PhD
13906500190
wxiaojia0803@163.com
Huanhuan ZHOU, MD
zhhuan77@163.com
Chaoqun Fei
0571-88123728
feicq@zjcc.org.cn
Zhejiang Cancer Hospital
Interventions
N/A
Study Locations (1 sites)
Zhejiang Cancer Hospital, Hangzhou, Zhejiang China
Eligibility Criteria
Inclusion Criteria: Local recurrent or metastatic breast cancer suitable for chemotherapy, confirmed histologically. HER2-negative breast cancer(according to 2018 ASCO/CAP HER2 test guideline). 18-75 years old. ECOG PS 0~2. life expectancy is not less than 12 weeks. at least one measurable lesion according to RECIST 1.1. received at least two cycles of SG. Signed informed Exclusion Criteria: Patients who did not receive sacituzumab govitecan treatment for two or more cycles Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma, have been diagnosed in the past five years. Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial History of neurological or psychiatric disorders Researchers believe that patients are not suitable for any other situation in this study.
Conditions Uncontrolled Asthma, Telemedicine-Based ...
Phase NA
Enrollment 64
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Asthma control in pediatric patients remains a critical issue for healthcare providers. Telemedicine has emerged as an effective solution for overcoming distance barriers in healthcare delivery. This study aims to utilize telemedicine-based education for caregivers to improve asthma control in children with uncontrolled asthma. By providing remote guidance and support, the study seeks to enhance caregivers' knowledge and management practices, ultimately leading to better asthma outcomes for pediatric patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Other: Telemedicine-Based Education — Intervention through telemedicine
  • Other: Standard Care (in control arm) — Sham comparator through telemedicine

Primary Outcomes

  • The improvement of asthma control (At second follow-up visit (ranging from 4 to 24 weeks after enrollment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-06-05
Completion: 2026-06
Eligibility
Age: 4 Years and older
Sex: ALL
Volunteers: false
Enrollment: 64 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Can Tho University of Medicine and Pharmacy
Principal Investigators:
  • Nghia Quang Bui, MD, PhD (STUDY_CHAIR) - Can Tho University of Medicine and Pharmacy
  • Ly Cong Tran, MD, MSc (STUDY_DIRECTOR) - Can Tho University of Medicine and Pharmacy
  • Thang Hoang Le, MD (PRINCIPAL_INVESTIGATOR) - Can Tho University of Medicine and Pharmacy
Contact Information
Study Contact:
Thang Hoang Le, MD
+84962024776
hoangthang0899@gmail.com
Ly Cong Tran, MD, MSc
+84397938208
tcly@ctump.edu.vn
Nghia Quang Bui, MD, PhD
+84918398788
bqnghia@ctump.edu.vn
Can Tho Children's Hospital
Interventions
  • Other: Telemedicine-Based Education — Intervention through telemedicine
  • Other: Standard Care (in control arm) — Sham comparator through telemedicine
Study Locations (1 sites)
Can Tho Children's Hospital, Can Tho, 900000 Vietnam
Eligibility Criteria
Inclusion Criteria: * Pediatric asthma patients diagnosed according to the GINA guidelines, classified as having uncontrolled asthma, are managed and followed up for at least 1 month at the pediatric asthma unit of the outpatient department. Exclusion Criteria: * Pediatric patients who do not cooperate or are unable to complete the Childhood Asthma Control Test questionnaire. * Caregivers who cannot complete the questionnaires related to the assessment of asthma control and associated factors. * Pediatric patients who have siblings participating in the study. * Patients currently participating in another clinical study (excluding non-interventional studies or registries). * Failure to return for a second visit within 6 months following enrollment.